Tech News
← Home  ·  All topics

Retatrutide

8 GoKawiil briefs on this topic · RSS for retatrutide

Eli Lilly's retatrutide shown to reduce sleep apnea episodes in trials

Two clinical trials found that Eli Lilly's experimental obesity drug retatrutide significantly cut the number of apnea episodes experienced by participants compared with those given a placebo. Retatrutide is already being studied as a potent weight-loss treatment, and the apnea findings represent an additional effect observed during testing.

Lab tests find bodega 'retatrutide' vials contain no peptide, bacteria instead

CBS News had a vial labeled retatrutide, bought at a Brooklyn bodega, tested by University of Iowa bioorganic chemist Jason Galpin, who found it contained phenylacetic acid rather than any peptide compound. A separate analysis by Carl Ross, the university's Center for Biocatalysis and Bioprocessing development director, identified at least 13 bacterial colonies in the sample. A similar Wired investigation last month on bodega-bought peptides also found no actual peptides, only an unidentifiable chemical mixture.

Penn researchers use AI to analyze Reddit reports on unapproved retatrutide use

University of Pennsylvania scientists analyzed roughly 150,000 Reddit posts from about 40,000 users to study self-reported effects of retatrutide, an experimental GLP-1 weight-loss drug not yet approved by regulators but obtained by some people in unapproved forms online. The study, published in JAMA Network Open, found that increased appetite was the most commonly reported symptom among classifiable complaints—contrary to the drug's hunger-suppressing design and the digestive issues emphasized in Phase 2 trials.

FDA Logs Two Deaths Tied to Black-Market Retatrutide

The FDA has received at least two reports of deaths connected to unapproved, black-market versions of retatrutide, an experimental weight-loss drug still being developed by Eli Lilly and not yet approved for sale. CBS News reviewed documents describing one case involving a 41-year-old obese woman who died of cardiac arrest in July after obtaining the drug from an unverified source. The FDA has not confirmed the counterfeit drug was the definitive cause of death in either case, and an April Medpage Today report also described a non-fatal retatrutide overdose causing kidney injury and prolonged dehydration.

Unapproved Weight-Loss Drug Retatrutide Sold Illegally Despite Lacking Regulatory Approval

Retatrutide, an experimental weight-loss drug not yet approved by any regulator, is reportedly being sold through unregulated channels alongside other peptides. Companies are distributing the compound outside normal pharmaceutical oversight, raising concerns about product safety and quality control.

Retatrutide trial shows 25% weight loss and eases knee pain, sleep apnea

Late-stage clinical trial results published in the New England Journal of Medicine show patients on the highest dose of retatrutide lost an average of 25% of body weight after 80 weeks, rising to 30% after 104 weeks. More than a third of participants lost 30% or more of their weight, and the drug also improved knee osteoarthritis pain, sleep apnea symptoms, and cardiometabolic markers including blood pressure and cholesterol.

WIRED lab tests find Brooklyn bodega 'peptide' vials contain no actual peptides

WIRED purchased four peptide products—PT-141, BPC-157, NAD+, and retatrutide—from a Brooklyn bodega for $376.20 and sent them to Finnrick, an Austin testing startup, for independent analysis. Results showed the vials had low levels of heavy metals and endotoxins but none of the active ingredients listed on their labels, meaning the products were either mislabeled or degraded beyond recognition.

Unapproved retatrutide knockoffs spread through black market ahead of FDA review

Counterfeit versions of retatrutide, an experimental Eli Lilly weight-loss drug not yet submitted for FDA approval, are being sold at spas and on social media despite lacking any regulatory clearance. The drug targets three hormone receptors to suppress appetite and boost calorie burn, with early trial data suggesting significant weight loss, but no legitimate US provider is authorized to prescribe it. ABC Australia reported a case where a counterfeit vial of the drug caused severe liver damage.